Novo Nordisk boosts lobbying as it seeks Medicare coverage for obesity drugs ...Middle East

The Hill - News
Novo Nordisk boosts lobbying as it seeks Medicare coverage for obesity drugs
Novo Nordisk, the maker of the weight loss drug Wegovy and diabetes medication Ozempic, went on a federal lobbying spending spree in the first six months of 2023. The Danish drugmaker is pushing Congress to pass a bill that would nix Medicare restrictions on covering weight management treatments. Novo Nordisk has hired three new lobbying firms over the past three months, all of which disclosed being solely focused on issues related to obesity and Medicare coverage of anti-obesity drugs. A 2003 law excludes weight-loss drugs from coverage under Medicare, the federal program that provides health coverage for older Americans. But since the American Medical Association recognized obe

Hence then, the article about novo nordisk boosts lobbying as it seeks medicare coverage for obesity drugs was published today ( ) and is available on The Hill ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Novo Nordisk boosts lobbying as it seeks Medicare coverage for obesity drugs )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News